May. 4 at 2:20 AM
$FATE FATE trades at a depressed 0.86 P/B with BVPS ~
$1.80 and stock ~
$1.53. Peers
$IPSC (2.5x P/B) and
$SANA (~5.5x P/B) suggest a rerate to
$4.50–
$9.90/share (or higher) at similar multiples. FATE is further ahead clinically with Phase 1 FT819 CAR-T data in autoimmune (SLE etc.) showing meaningful responses, while IPSC and SANA remain mostly pre-IND or earlier in comparable programs. Strong data could easily justify a 4–7x+ P/B premium given the iPSC leadership and de-risking. High risk/high reward—watch the next readouts. DYOR.
